omniture
logo
Search
CLARITY PHARMACEUTICALS
Media Room

Photo News

rss
Copper-67 SAR-bisPSMA updates

Copper-67 SAR-bisPSMA updates

2024-10-16 21:03 2249
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort

2024-09-12 21:03 1803
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range

2024-03-08 22:02 2041
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

2023-11-30 21:59 1627
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

2023-08-25 20:58 2735
Clarity's theranostic prostate cancer trial advances to cohort 2

Clarity's theranostic prostate cancer trial advances to cohort 2

2023-05-24 21:03 2745
Fifty percent recruitment milestone for PROPELLER prostate cancer trial

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

2021-12-01 21:57 1610
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

2021-11-10 22:06 1771